Does FDA clearance of a PRP kit approve the treatment?

FDA clearance of a named platelet-rich-plasma preparation kit applies to that device, model and exact intended use; it does not automatically approve PRP as a treatment for hair loss, facial aging, sexual function, orthopedic conditions, scars, or post-microneedling delivery. A clinic must separate the kit’s 510(k) record from the clinical indication, processing protocol, administration route, evidence and practitioner scope.¹²³

A PRP service contains at least four regulatory objects

A clinic may draw blood with standard supplies, process it in a centrifuge and kit, create a platelet-containing preparation, then inject or apply it for a proposed purpose. “FDA-cleared PRP” can refer imprecisely to any link in that chain.

This separation keeps “the kit is cleared” from becoming “FDA approved my treatment.”

Read the indication sentence, not the seal

FDA’s current biological-device pages list named PRP systems with bounded indications. Some authorize preparation of autologous PRP for mixing with autograft or allograft bone to improve handling—not injection into a scalp, face, joint or sexual organ.¹

The 2025 PlateletQuick PRP summary describes a Class II device cleared through substantial equivalence for rapid preparation of autologous PRP and mixing with bone graft for bony defects.² Device-performance and biocompatibility testing do not become clinical efficacy evidence for unrelated injections.

Ask to see the actual clearance number and summary. Match manufacturer, system/model and components to what is on the tray. “FDA registered,” “Class II,” “medical-grade centrifuge,” “510(k) exempt,” and a generic product code each mean something different and are not substitutes for the exact record.

Clearance is not PMA approval—and neither is category wide

The 510(k) pathway generally asks whether a device is substantially equivalent to a legally marketed predicate for its intended use and technological characteristics.³ FDA ordinarily calls the result “cleared,” not “approved.” The device-pathway guide explains why PMA, De Novo and 510(k) should not be flattened into an “FDA approved” badge.

Even a device clearance does not transfer automatically to a newer model, third-party tube, altered spin, unlisted activator or a different use. Verify current status and labeling rather than assuming a family resemblance.

Treatment evidence must describe the prepared product

PRP studies vary in participant diagnosis, blood volume, spins, platelet concentration, leukocyte content, activation, injection depth, number and spacing of sessions, comparator and outcome. “PRP worked in a study” is not enough to reproduce an intervention.

For male pattern hair loss, a 2024 review found some hair-count or density signals across a small set of studies but characterized the evidence as low quality, moderately biased and heterogeneous.⁵ That cannot support guaranteed regrowth, every cause of hair loss or every kit. Scarring alopecia, shedding, nutritional or endocrine causes and androgenetic loss require different diagnostic ownership.

The same rule applies to face, joint or sexual-health claims: use condition-specific evidence and do not move an outcome from one tissue to another because both used autologous blood.

Microneedling creates a separate delivery question

FDA’s microneedling guidance lists delivery of cosmetics, topical medications, vitamin solutions, drugs and blood products such as PRP among uses the devices are not approved to perform.⁴ Treat delivery as a separate regulatory question: the PRP kit’s clearance cannot rewrite the pen’s labeling, and the pen’s clearance cannot authorize PRP delivery.

The infection-control chain also changes when blood is handled around a procedure that creates skin channels. The clinic should show single-patient supplies, surface barriers, centrifuge cleaning, splash protection, labeling, sharps and biohazard handling, handoff between staff and what happens to unused product. Autologous does not mean sterile by definition.

“Your own blood” does not remove clinical risk

Risks can arise from the blood draw, anticoagulant or additives, contamination, handling, injection, anatomy, inflammation and the underlying condition. Ask about bruising, pain, infection, nerve or vascular injury, scarring, pigment change, shedding and procedure-specific serious events. The response pathway should name who evaluates a concern and where urgent care occurs.

Clinic terms should also say whether payment covers the kit, clinician assessment, imaging if relevant, anesthesia, repeat sessions, photos, follow-up and management of an adverse event. A multi-session package should not precommit someone before the response to session one is known.

1. Identify the exact kit Match manufacturer, model and clearance number to the device used, then read the intended-use sentence.
2. Name the clinical claim separately State condition, route, site, schedule and endpoint without using kit clearance as treatment evidence.
3. Make the preparation reproducible Record blood, anticoagulant, spins, output, additives and lot information.
4. Match evidence to protocol Require the same diagnosis and a sufficiently similar PRP formulation and delivery plan.
5. Audit sterile handling and ownership Verify licensed roles, blood-control workflow, follow-up and complication escalation.

The strongest PRP consultation can say two true things at once: an exact preparation device may be FDA cleared, and the proposed treatment still needs its own evidence and consent.